Search Results - "Wieland, Amanda"

  • Showing 1 - 14 results of 14
Refine Results
  1. 1

    Optimizing hepatitis C virus treatment through pharmacist interventions: Identification and management of drug-drug interactions by Langness, Jacob A, Nguyen, Matthew, Wieland, Amanda, Everson, Gregory T, Kiser, Jennifer J

    Published in World journal of gastroenterology : WJG (07-03-2017)
    “…AIM To quantify drug-drug-interactions(DDIs) encountered in patients prescribed hepatitis C virus(HCV) treatment, the interventions made, and the time spent in…”
    Get full text
    Journal Article
  2. 2

    Single-cell transcriptomic analyses of T cells in chronic HCV-infected patients dominated by DAA-induced interferon signaling changes by Burchill, Matthew A, Salomon, Matthew P, Golden-Mason, Lucy, Wieland, Amanda, Maretti-Mira, Ana C, Gale, Michael, Rosen, Hugo R

    Published in PLoS pathogens (09-08-2021)
    “…Chronic infection with HCV is manifested by dysregulation of innate immune responses and impaired T cell function at multiple levels. These changes may impact…”
    Get full text
    Journal Article
  3. 3

    Low Awareness of Nonalcoholic Fatty Liver Disease Among Patients at High Metabolic Risk by Wieland, Amanda C, Mettler, Pamela, McDermott, Michael T, Crane, Lori A, Cicutto, Lisa C, Bambha, Kiran M

    Published in Journal of clinical gastroenterology (01-01-2015)
    “…GOALS:To assess awareness of nonalcoholic fatty liver disease (NAFLD) as a disease entity among individuals with and without metabolic risk factors in an…”
    Get full text
    Journal Article
  4. 4

    Identifying Practice Gaps to Optimize Medical Care for Patients with Nonalcoholic Fatty Liver Disease by Wieland, Amanda C., Quallick, Matthew, Truesdale, Aimee, Mettler, Pamela, Bambha, Kiran M.

    Published in Digestive diseases and sciences (01-10-2013)
    “…Background Nonalcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease. Primary care providers (PCPs), in contrast to…”
    Get full text
    Journal Article
  5. 5

    Curing Chronic Hepatitis C: A Cost Comparison of the Combination Simeprevir Plus Sofosbuvir vs. Protease-Inhibitor-Based Triple Therapy by Langness, Jacob A, Tabano, David, Wieland, Amanda, Tise, Sarah, Pratt, Lindsay, Ayres Harrington, Lauren, Lin, Sonia, Ghuschcyan, Vahram, Nair, Kavita V, Everson, Gregory T

    Published in Annals of hepatology (01-05-2017)
    “…AbstractIntroductionInterferon-free, multi-direct acting antiviral (DAA) therapy for chronic hepatitis C virus (HCV) infection is highly effective and well…”
    Get full text
    Journal Article
  6. 6

    Non-Alcoholic Steatohepatitis as a Growing Indication for Liver Transplantation: The Evolving Gender and Ethnic Trends by Wieland, Amanda, Kohli, Ruhail

    Published in The American journal of gastroenterology (01-11-2018)
    “…With highly effective cures for hepatitis C and rising rates of metabolic disease in the United States, the composition of the liver transplant candidate pool…”
    Get full text
    Journal Article
  7. 7
  8. 8

    Lean NAFLD: an underrecognized and challenging disorder in medicine by Maier, Sheila, Wieland, Amanda, Cree-Green, Melanie, Nadeau, Kristen, Sullivan, Shelby, Lanaspa, Miguel A., Johnson, Richard J., Jensen, Thomas

    Published in Reviews in endocrine & metabolic disorders (01-06-2021)
    “…Classically, Non-Alcoholic Fatty Liver Disease (NAFLD) has been thought to be driven by excessive weight gain and obesity. The overall greater awareness of…”
    Get full text
    Journal Article
  9. 9

    HepQuant SHUNT Detects Portal Hypertension in Early Stages of Clinically Compensated Chronic Liver Disease by Wieland, Amanda, Etzion, Ohad, Ali, Rabab O., Levy, Elliot, Kleiner, David E., Helmke, Steve M., Heller, Theo, Everson, Gregory T.

    Published in Clinical gastroenterology and hepatology (01-04-2022)
    “…Physicians use portal pressure measurements in clinical practice and research but the methods are invasive, can cause complications, and are resource…”
    Get full text
    Journal Article
  10. 10

    Co-existing Hepatitis C and Alcoholic Liver Disease: A Diminishing Indication for Liver Transplantation? by Wieland, Amanda, Everson, Gregory T

    Published in Alcohol and alcoholism (Oxford) (01-03-2018)
    “…Abusive alcohol use and chronic hepatitis C virus (HCV) commonly co-exist and both need to be addressed in liver disease. With high rates of HCV cure with new…”
    Get full text
    Journal Article
  11. 11
  12. 12

    Clinical workup of fatty liver for the primary care provider by Jensen, Thomas, Wieland, Amanda, Cree-Green, Melanie, Nadeau, Kristen, Sullivan, Shelby

    Published in Postgraduate medicine (02-01-2019)
    “…Nonalcoholic fatty liver disease (NAFLD) is quickly emerging as a global epidemic in parallel with the rise in obesity and the Metabolic Syndrome. NAFLD, once…”
    Get full text
    Journal Article
  13. 13

    Early and late changes in natural killer cells in response to ledipasvir/sofosbuvir treatment by Golden‐Mason, Lucy, McMahan, Rachel H., Kriss, Michael S., Kilgore, Alexandra L., Cheng, Linling, Dran, Rachael J., Wieland, Amanda, Rosen, Hugo R.

    Published in Hepatology communications (01-04-2018)
    “…Chronic hepatitis C virus (HCV) infection is characterized by dysregulated natural killer (NK) cell responses. NKs play a critical role in achieving sustained…”
    Get full text
    Journal Article
  14. 14

    Curing Chronic Hepatitis C: A Cost Comparison of the Combination Simeprevir Plus Sofosbuvir vs. Protease-Inhibitor-Based Triple Therapy by Langness, Jacob A, Tabano, David, Wieland, Amanda, Tise, Sarah, Pratt, Lindsay, Ayres Harrington, Lauren, Lin, Sonia, Ghuschcyan, Vahram, Nair, Kavita V, Everson, Gregory T

    Published in Annals of hepatology (01-05-2017)
    “…Interferon-free, multi-direct acting antiviral (DAA) therapy for chronic hepatitis C virus (HCV) infection is highly effective and well tolerated, but costly…”
    Get full text
    Journal Article